UK MHRA Accepts Savara's Molbreevi Marketing Application for Autoimmune PAP
SVRA has more than doubled off its 52-week low of $1.89.
Summary
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted Savara Inc.'s Marketing Authorisation Application (MAA) for Molbreevi to treat Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP). This is a significant positive regulatory step, building on the FDA's prior grant of Priority Review for the same drug, as highlighted in the company's recent 10-K. The MHRA's acceptance de-risks Molbreevi's path to market in the UK and expands its potential commercial reach beyond the US. Investors will now closely monitor the MHRA's decision, expected in Q4 2026, alongside the FDA's PDUFA date on August 22, 2026, and the CHMP decision in Q1 2027.
At the time of this announcement, SVRA was trading at $5.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $1.89 to $7.01. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.